5 Key Takeaways

• 1

  Manufacturing challenges hinder the widespread adoption of cell and gene therapies.

• 2

  Stable cell lines and process intensification are key to improving manufacturing scalability.

• 3

  AI-driven process modeling and quality-by-design enhance output while ensuring product quality.

• 4

  Flexible manufacturing models and advanced analytical technologies support diverse therapeutic needs.

• 5

  Regulatory flexibility and data-led process control are crucial for large-scale commercialization.